Poolbeg Pharma's (LON:POLB) Jeremy Skillington joins Proactive London's Katie Pilbeam on the first day of their London market listing on AIM.
The firm is a spin-out of Open Orphan who have successfully completed an oversubscribed fundraise which resulted in an increased raise from £20m to £25m.
At a share price of 10p per share the firm's market cap at admission is £50m.
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model.